Universal and Stemness-Related Tumor Antigens: Potential Use in Cancer Immunotherapy
暂无分享,去创建一个
A. Marrari | G. Parmiani | C. Castelli | L. Rivoltini | C. Maccalli | C. Casati | V. Russo | L. Pilla | Gianluca Cutolo
[1] Michael F. Clarke,et al. Phenotypic characterization of human colorectal cancer stem cells , 2007, Proceedings of the National Academy of Sciences.
[2] G. Parmiani,et al. Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1 , 2007, The Journal of Immunology.
[3] I. Weissman,et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma , 2007, Proceedings of the National Academy of Sciences.
[4] M. Clarke,et al. Cancer stem cells: models and concepts. , 2007, Annual review of medicine.
[5] J. Dick,et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.
[6] L. Ricci-Vitiani,et al. Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.
[7] G. Gaudernack,et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study , 2006, British Journal of Cancer.
[8] J. Dick,et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.
[9] A. Anichini,et al. Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell–Mediated Patient-Specific Immunotherapy , 2006, Clinical Cancer Research.
[10] Peter T Masiakos,et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[11] E. Rieber,et al. Vaccination of hormone‐refractory prostate cancer patients with peptide cocktail‐loaded dendritic cells: Results of a phase I clinical trial , 2006, The Prostate.
[12] Thierry Boon,et al. Human T cell responses against melanoma. , 2006, Annual review of immunology.
[13] H. Li,et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells , 2006, Oncogene.
[14] S. Aamdal,et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer , 2006, Cancer Immunology, Immunotherapy.
[15] G. Damonte,et al. Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. , 2006, Blood.
[16] P. Dalerba,et al. Identification of pancreatic cancer stem cells. , 2006, Cancer research.
[17] C. Huber,et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[18] D. Elder,et al. A tumorigenic subpopulation with stem cell properties in melanomas. , 2005, Cancer research.
[19] Danila Coradini,et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. , 2005, Cancer research.
[20] Mads Hald Andersen,et al. Regulators of apoptosis: suitable targets for immune therapy of cancer , 2005, Nature Reviews Drug Discovery.
[21] F. Lozupone,et al. Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? , 2005, Expert opinion on biological therapy.
[22] Donna Niedzwiecki,et al. Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer 1 , 2005, The Journal of Immunology.
[23] G. Parmiani,et al. A listing of human tumor antigens recognized by T cells: March 2004 update , 2005, Cancer Immunology, Immunotherapy.
[24] J. Becker,et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. , 2005, Vaccine.
[25] Ugo Orfanelli,et al. Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.
[26] S. Rosenberg,et al. Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.
[27] S. Rosenberg,et al. Immunization of Patients with the hTERT:540-548 Peptide Induces Peptide-Reactive T Lymphocytes That Do Not Recognize Tumors Endogenously Expressing Telomerase , 2004, Clinical Cancer Research.
[28] W. Hahn,et al. Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes , 2004, Clinical Cancer Research.
[29] P. Dalerba,et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. , 2003, Cancer research.
[30] L. Kanz,et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. , 2003, Blood.
[31] S. Morrison,et al. Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[32] E. Gilboa,et al. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. , 2002, Cancer research.
[33] Francesco M Marincola,et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? , 2002, Journal of the National Cancer Institute.
[34] Jingwu Z. Zhang,et al. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. , 2002, Cancer research.
[35] W. Hahn,et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. , 2001, Cancer research.
[36] J. Becker,et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. , 2001, Cancer research.
[37] P. Robbins,et al. A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.
[38] E. Thiel,et al. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. , 2000, Cancer research.
[39] H. Rammensee,et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. , 2000, Cancer research.
[40] J. Hipp,et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[41] D. Altieri,et al. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[42] W. Hahn,et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. , 1999, Immunity.
[43] C. Farina,et al. Translation of a Retained Intron in Tyrosinase-related Protein (TRP) 2 mRNA Generates a New Cytotoxic T Lymphocyte (CTL)-defined and Shared Human Melanoma Antigen Not Expressed in Normal Cells of the Melanocytic Lineage , 1998, The Journal of experimental medicine.
[44] S. Rosenberg,et al. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. , 1997, Journal of immunology.
[45] J. Bryant,et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. , 1996, The Journal of clinical investigation.
[46] F. Brasseur,et al. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N- acetylglucosaminyltransferase V gene , 1996, The Journal of experimental medicine.
[47] M. Caligiuri,et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.
[48] A. Anichini,et al. Heterogeneity of clones from a human metastatic melanoma detected by autologous cytotoxic T lymphocyte clones , 1986, The Journal of experimental medicine.
[49] M. Carpenter,et al. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. , 2004, Vaccine.
[50] J. Diebold,et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. , 1998, The American journal of pathology.